Post-traumatic Stress Disorder | Treatment of PTSD by Reduction of Traumatic Memory Reconsolidation by Propranolol : a Multisite Trial

Post-traumatic Stress Disorder research study

What is the primary objective of this study?

The purpose of this study is to test whether propranolol, when given during a re-evocation of a traumatic memory, is capable of reducing subsequent PTSD symptoms associated with that memory.

Who is eligible to participate?

Inclusion Criteria: - Diagnosis of chronic PTSD - PTSD CheckList total score >44 Exclusion Criteria: - Systolic blood pressure < 100 mmHg - Contraindication to Propranolol - Previous adverse reaction to a β-blocker - Use of another β-blocker - Use of medication that could involve potentially dangerous interactions with propranolol - Psychotherapy or treatment with any pharmacologic PTSD medication within the 2 weeks prior to inclusion (6 weeks for fluoxetine) - Female with reproductive potential without reliable means of contraception - Pregnancy or lactation - Alcohol or drug abuse

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Post-traumatic Stress Disorder

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.


Other:Trauma reactivationTrauma reactivation: script-driven mental imagery of the traumatic event


Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Propranolol + reactivationthey have a script-driven mental imagery of the traumatic event white drug

Placebo + reactivationThey have a script-driven mental imagery of the traumatic event with placebo

Study Status

Unknown status

Start Date: November 2012

Completed Date: November 2017

Phase: Phase 2

Type: Interventional


Primary Outcome: PTCD CheckList (PCL) total score.

Secondary Outcome:

Study sponsors, principal investigator, and references

Principal Investigator: Philippe BIRMES, MD

Lead Sponsor: University Hospital, Toulouse


More information:

Discuss Propranolol